Febuxostat - Teijin Pharma
Alternative Names: Adenuric; Feburic; Febuxostat XR; TEI-6720; TMX 67XR; TMX-67; TMX-67HK; TURAZIVE; UloricLatest Information Update: 05 Nov 2023
At a glance
- Originator Teijin Pharma
- Developer Astellas Pharma; Ipsen; Menarini; SK Chemicals; Takeda Pharmaceuticals USA; Te Arai BioFarma; Teijin Pharma
- Class Antigouts; Carboxylic acids; Ischaemic heart disorder therapies; Nitriles; Phenyl ethers; Small molecules; Thiazoles; Uricosurics
- Mechanism of Action Xanthine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Gout; Hyperuricaemia
- Registered Tumour lysis syndrome
- Suspended Angina pectoris
Most Recent Events
- 26 Jun 2023 Registered for Gout (In children) in Japan (PO)
- 26 Jun 2023 Registered for Hyperuricaemia (In children) in Japan (PO)
- 01 Jun 2022 Efficacy data from a phase IIIb CARES trial for Hyperuricaemia (in patients with gout and cardiovascular co-morbidities) presented at the 23rd Annual Congress of the European League Against Rheumatism (EULAR-2022)